Chardan Capital Comments on uniQure FY2025 Earnings

uniQure (NASDAQ:QURE) – Investment analysts at Chardan Capital issued their FY2025 earnings estimates for uniQure in a research report issued to clients and investors on Tuesday, April 1st. Chardan Capital analyst Y. Livshits forecasts that the biotechnology company will earn ($3.90) per share for the year. Chardan Capital has a “Buy” rating and a $38.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. Chardan Capital also issued estimates for uniQure’s FY2026 earnings at ($3.23) EPS.

A number of other research analysts also recently weighed in on QURE. The Goldman Sachs Group upped their price target on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Stifel Nicolaus boosted their price target on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 16th. Leerink Partners upped their price objective on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of uniQure in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average target price of $38.80.

uniQure Price Performance

QURE stock opened at $8.96 on Thursday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The company’s 50-day moving average is $13.25 and its 200-day moving average is $10.91. The stock has a market capitalization of $484.53 million, a PE ratio of -1.81 and a beta of 0.37. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18.

Insider Buying and Selling

In other news, CEO Matthew C. Kapusta sold 6,717 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $76,036.44. Following the completion of the transaction, the chief executive officer now directly owns 580,795 shares of the company’s stock, valued at $6,574,599.40. This represents a 1.14 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christian Klemt sold 14,341 shares of uniQure stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the sale, the chief financial officer now directly owns 152,372 shares in the company, valued at $1,630,380.40. This trade represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 90,830 shares of company stock worth $961,401. 4.74% of the stock is owned by company insiders.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its holdings in uniQure by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock valued at $1,367,000 after purchasing an additional 16,464 shares during the last quarter. FMR LLC raised its position in shares of uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares during the period. PEAK6 Investments LLC purchased a new stake in shares of uniQure during the 3rd quarter valued at approximately $260,000. Walleye Capital LLC bought a new position in uniQure in the 3rd quarter worth approximately $444,000. Finally, Point72 Asset Management L.P. grew its stake in uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after buying an additional 752,889 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.